SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). “We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients.

SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints

- 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit -

SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, and members of the SELLAS management team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference, taking place in New York, NY, from September 26-28, 2023.

SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference

REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC). The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications.

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia with Topline Data Expected in 4Q 2023

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy with 40% of Patients Alive as of Last Follow-Up; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks 30% Disease Control Rate per RECIST Criteria No Dose Limiting Toxicities Observed NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced topline clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with malignant pleural mesothelioma (MPM) who were either refractory to or relapsed after at least one line of the standard of care therapy. Nine of the ten patients enrolled received at least three doses of GPS, with the third GPS dose given in combination with nivolumab.

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first patient has been dosed in a Phase 2a study of its novel and highly selective CDK9 inhibitor, GFH009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies. Topline data is expected during the fourth quarter of this year.

SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2023) which will be held November 5-7, 2023, in Seoul, South Korea.

SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting

NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, has been invited to participate in a fireside chat at the Maxim Group Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, taking place June 20-22, 2023.

SELLAS to Participate in Maxim Group Healthcare Virtual Conference

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for the Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago.

SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced it will host a virtual panel discussion on Tuesday, May 30, 2023 at 8:00 a.m. EST. The panel will feature hematology-oncology specialists Tapan Kadia, MD (The University of Texas MD Anderson Cancer Center), Joshua Zeidner, MD (University of North Carolina Lineberger Comprehensive Cancer Center), and Omer Jamy, MD (O'Neal Comprehensive Cancer Center at the University of Alabama) who will discuss the treatment landscape for acute myeloid leukemia (AML) and the potential for GFH009 to address unmet medical needs for patients with relapsed and/or refractory AML.

SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia

Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient with Acute Myeloid Leukemia > 6 months

SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually.

SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting

– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once weekly dosing –

SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia

Next IDMC Meeting Scheduled for Q3 2023 REGAL on Track for Interim Analysis by Late 2023/Early 2024 NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The Independent Data Monitoring Committee (IDMC) performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications.

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

Enovis Corp

Esperion Therapeutics

Edgewise Therapeutics

Senseonics Holdings

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal

Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which is focused on cancer treatments, plummeted 43.1% in premarket trading, after the offering was initially announced without terms late Thursday.

Sellas Life Sciences raises $20 million from public offering of stock, warrants

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 7,220,217 shares of its common stock and accompanying warrants to purchase up to 7,220,217 shares of common stock at a combined public offering price of $2.77 per share and accompanying warrant. The warrants to purchase shares of common stock have an exercise price of $2.77 per share, are immediately exercisable and will expire five years from the date of issuance. All of the securities in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $20.0 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on February 28, 2023, subject to the satisfaction of customary closing conditions.

SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering

SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public offering. According to a press release, SELLAS Life Sciences intends to offer up shares of SLS stock, as well as warrants to purchase shares of the stock.

Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?

NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities in the offering will be sold by SELLAS.

SELLAS Life Sciences Announces Proposed Underwritten Public Offering

Galena Biopharma, Inc. (SLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University of Alabama Participating Site

SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program

Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug Approvals Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug Approvals

News for SELLAS Life Sciences Group Stock (SLS)